Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01574-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Laure-Hélène Préta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm, Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, 75006, Paris, France. laurehelene.p…. Hauptthemen laut MEDLINE: Maternal Exposure, Selective Serotonin Reuptake Inhibitors, Maternal-Fetal Exchange, Placenta. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Fondation pour la Recherche Médicale (FRM), Groupement d'intérêt scientifique - Centre français pour les 3R (GIS-FC3R), Groupement d’intérêt scientifique - Centre français pour les 3R.
Abstract (Originalsprache)
BACKGROUND: Depression is common in pregnant women, and selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants during pregnancy. Pregnancy is a period of major physiological changes that impact drug pharmacokinetics (PK). To date, there is limited information about the placental transfer of antidepressants, and differences in fetal exposure between drugs are poorly characterized. AIMS: We aimed to develop physiologically based pharmacokinetic (PBPK) models to assess maternal and fetal exposure to sertraline, escitalopram and paroxetine across pregnancy. METHODS: Transplacental parameters from ex vivo human placenta perfusion experiments were estimated using mixed-effects modeling in Monolix and integrated in pregnancy PBPK models in Simcyp PBPK Simulator. After evaluation of the models by comparison with observed data from literature, maternal PK profiles and fetal exposure at different trimesters of pregnancy were simulated. RESULTS: The pregnancy PBPK models accurately predicted maternal and fetal concentration time-courses of SSRIs. Simulations showed a decrease in maternal concentrations during pregnancy for all three SSRIs, affecting both total and unbound concentrations. In the third trimester, residual concentrations were predicted to decrease by 56% and 43% for sertraline, 55% and 49% for escitalopram, and 90% and 88% for paroxetine, for total and unbound concentrations respectively. Cord blood-to-maternal plasma area-under-curve (fm AUC) ratios over 24 h were calculated based on model predictions. By late pregnancy, fm AUC ratios were 0.45 for sertraline, 0.91 for escitalopram, and 0.58 for paroxetine. CONCLUSIONS: Quantitative prediction of antidepressants exposure using PBPK modeling integrating ex vivo data will help to better understand the impact of pregnancy-related physiological changes on the PK of these drugs and support evidence-based pharmacotherapy for depression during pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Inserm, Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, 75006, Paris, France. laurehelene.preta@aphp.fr.
- Université Paris Cité, Inserm, Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte, 75006, Paris, France.
- Unité de Recherche Clinique, Université Paris Cité Necker/Cochin, Hôpital Tarnier, Paris, France.
- CIC-1419 Inserm, Cochin-Necker, Paris, France.
- Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, Paris, France.
ORCID-Profile: Laure-Hélène Préta
Förderung
- Fondation pour la Recherche Médicale (FRM)
- Groupement d'intérêt scientifique - Centre français pour les 3R (GIS-FC3R)
- Groupement d’intérêt scientifique - Centre français pour les 3R
Zitieren
APA
Préta, L. H., Bouazza, N., Foissac, F., Froelicher, L., Urien, S., Buth, V., Benaboud, S., Tréluyer, J. M., & Lui, G. (2025). Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01574-5
Vancouver
Préta LH, Bouazza N, Foissac F, Froelicher L, Urien S, Buth V, et al. Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01574-5
BibTeX
@article{Prta2025,
author = {Préta, Laure-Hélène and Bouazza, Naïm and Foissac, Frantz and Froelicher, Léo and Urien, Saïk and Buth, Victoria and Benaboud, Sihem and Tréluyer, Jean-Marc and Lui, Gabrielle},
title = {Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01574-5}
}
EUVIMED